Cell Source, Inc. (CLCS)
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Cell Source, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 67.95M shares outstanding
USCell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance.
The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Leadership
Itamar Shimrat
Chief Executive Officer, President & Chief Financial Officer
Dennis Brown
Executive Chairman
Employees
1
Country
US
Sector
Healthcare
Website
cell-source.com
based on 67.95M shares outstanding
US30d Avg
2.29K
60d Avg
3.15K
90d Avg
3.57K